Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment

[1]  I. Hirsch,et al.  Why Are We Failing to Address the Issue of Access to Insulin? A National and Global Perspective , 2018, Diabetes Care.

[2]  M. Beckett,et al.  A cross-sectional analysis of the relationship between diabetes and health access barriers in an urban First Nations population in Canada , 2018, BMJ Open.

[3]  S. Basu,et al.  Validation of Risk Equations for Complications of Type 2 Diabetes (RECODe) Using Individual Participant Data From Diverse Longitudinal Cohorts in the U.S. , 2017, Diabetes Care.

[4]  R. Shrestha,et al.  Survey on the availability, price and affordability of selected essential medicines for non-communicable diseases in community pharmacies of Kathmandu valley , 2017, SAGE open medicine.

[5]  Xinping Zhang,et al.  Insulin prices, availability and affordability: a cross-sectional survey of pharmacies in Hubei Province, China , 2017, BMC Health Services Research.

[6]  Juliet Nabbaale,et al.  Access to medicines and diagnostic tests integral in the management of diabetes mellitus and cardiovascular diseases in Uganda: insights from the ACCODAD study , 2017, International Journal for Equity in Health.

[7]  D. Beran,et al.  The role of biosimilar manufacturers in improving access to insulin globally. , 2017, The lancet. Diabetes & endocrinology.

[8]  W. Herman,et al.  Why Are Diabetes Medications So Expensive and What Can Be Done to Control Their Cost? , 2017, Current Diabetes Reports.

[9]  I. Hirsch,et al.  Human Insulin for Type 2 Diabetes: An Effective, Less-Expensive Option. , 2017, JAMA.

[10]  B. Zinman,et al.  Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes , 2017, The New England journal of medicine.

[11]  A. Śliwczyński,et al.  Drug-class-specific changes in the volume and cost of antidiabetic medications in Poland between 2012 and 2015 , 2017, PloS one.

[12]  A. Kesselheim,et al.  Strategies to improve the affordability of insulin in the USA. , 2017, The lancet. Diabetes & endocrinology.

[13]  M. Zweekhorst,et al.  Baseline assessment of WHO’s target for both availability and affordability of essential medicines to treat non-communicable diseases , 2017, PloS one.

[14]  D. Flood,et al.  Perceptions and utilization of generic medicines in Guatemala: a mixed-methods study with physicians and pharmacy staff , 2017, BMC Health Services Research.

[15]  H. Fu,et al.  Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes , 2016, Journal of managed care & specialty pharmacy.

[16]  W. Kaplan,et al.  Challenges constraining access to insulin in the private-sector market of Delhi, India , 2016, BMJ Global Health.

[17]  K. Nyarko,et al.  Capacity assessment of selected health care facilities for the pilot implementation of Package for Essential Non-communicable Diseases (PEN) intervention in Ghana , 2016, The Pan African medical journal.

[18]  T. Gill,et al.  Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013 , 2016, Diabetes Care.

[19]  W. Maier,et al.  Does charge-free screening improve detection of gestational diabetes in women from deprived areas: a cross-sectional study , 2016, BMC Pregnancy and Childbirth.

[20]  W. Polonsky,et al.  Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors , 2016, Patient preference and adherence.

[21]  J. Park,et al.  Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002–2013 , 2016, Medicine.

[22]  A. Berghold,et al.  Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. , 2016, The Cochrane database of systematic reviews.

[23]  J. Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[24]  J. Miranda,et al.  Delivery of Type 2 diabetes care in low‐ and middle‐income countries: lessons from Lima, Peru , 2016, Diabetic medicine : a journal of the British Diabetic Association.

[25]  P. Sakthong,et al.  Cost-Effectiveness Analysis of the Self-Management Program for Thai Patients with Metabolic Syndrome. , 2016, Value in health regional issues.

[26]  Michelle Tew,et al.  Expenditures and Prices of Antihyperglycemic Medications in the United States: 2002-2013. , 2016, JAMA.

[27]  M. Riddle.  Lessons From Peglispro: IMAGINE How to Improve Drug Development and Affordability , 2016, Diabetes Care.

[28]  D. Beran,et al.  Constraints and challenges in access to insulin: a global perspective. , 2016, The lancet. Diabetes & endocrinology.

[29]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[30]  P. Bach.  New Math on Drug Cost-Effectiveness. , 2015, The New England journal of medicine.

[31]  I. Hirsch,et al.  Costs Associated With Using Different Insulin Preparations. , 2015, JAMA.

[32]  C. Horowitz,et al.  Disparities in diabetes management in Asian Americans in New York City compared with other racial/ethnic minority groups. , 2015, American journal of public health.

[33]  O. Awodele,et al.  Medication adherence in type 2 diabetes patients: study of patients in Alimosho General Hospital, Igando, Lagos, Nigeria. , 2015, African health sciences.

[34]  D. Beran,et al.  Medicines availability for non-communicable diseases: the case for standardized monitoring , 2015, Globalization and Health.

[35]  I. Hutter,et al.  “It is the medicines that keep us alive”: lived experiences of diabetes medication use and continuity among adults in Southeastern Tanzania , 2015, BMC Health Services Research.

[36]  D. Beran.  The Impact of Health Systems on Diabetes Care in Low and Lower Middle Income Countries , 2015, Current Diabetes Reports.

[37]  E. Gregg,et al.  Change in Medical Spending Attributable to Diabetes: National Data From 1987 to 2011 , 2015, Diabetes Care.

[38]  W. Herman,et al.  Determinants of Adherence to Diabetes Medications: Findings From a Large Pharmacy Claims Database , 2015, Diabetes Care.

[39]  A. Kengne,et al.  Access to Diagnostic Tests and Essential Medicines for Cardiovascular Diseases and Diabetes Care: Cost, Availability and Affordability in the West Region of Cameroon , 2014, PloS one.

[40]  Roland J Thorpe,et al.  Disparities in diabetes: the nexus of race, poverty, and place. , 2014, American journal of public health.

[41]  J. Hughes,et al.  An evaluation of patients’ adherence with hypoglycemic medications among Papua New Guineans with type 2 diabetes: influencing factors , 2014, Patient preference and adherence.

[42]  C. Wanigatunge,et al.  A national survey on availability, price and affordability of selected essential medicines for non communicable diseases in Sri Lanka , 2014, BMC Public Health.

[43]  J. Ross,et al.  Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010. , 2014, JAMA.

[44]  L. Smeeth,et al.  Preparedness of Tanzanian health facilities for outpatient primary care of hypertension and diabetes: a cross-sectional survey , 2014, The Lancet. Global health.

[45]  A. Worku,et al.  Barriers to diabetes medication adherence in North West Ethiopia , 2014, SpringerPlus.

[46]  W. Brouwer,et al.  Measuring the affordability of medicines: importance and challenges. , 2013, Health policy.

[47]  M. Mckee,et al.  Diabetes in Kyrgyzstan: changes between 2002 and 2009. , 2013, The International journal of health planning and management.

[48]  D. Beran,et al.  Delivering Diabetes Care in the Philippines and Vietnam , 2013, Asia-Pacific journal of public health.

[49]  S. Mendis,et al.  Gaps in Capacity in Primary Care in Low-Resource Settings for Implementation of Essential Noncommunicable Disease Interventions , 2012, International journal of hypertension.

[50]  Amitava Banerjee,et al.  Tracking global funding for the prevention and control of noncommunicable diseases. , 2012, Bulletin of the World Health Organization.

[51]  W. Brouwer,et al.  Practical measurement of affordability: an application to medicines. , 2012, Bulletin of the World Health Organization.

[52]  M. Orzanco,et al.  Rural-urban disparities in the management and health issues of chronic diseases in Quebec (Canada) in the early 2000s. , 2010, Rural and remote health.

[53]  J. Yudkin,et al.  The Diabetes UK Mozambique Twinning Programme. Results of improvements in diabetes care in Mozambique: a reassessment 6 years later using the Rapid Assessment Protocol for Insulin Access , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[54]  Mixtard 30 - going, going, gone? , 2010, Drug and Therapeutics Bulletin.

[55]  E. Gale,et al.  Estimation of primary care treatment costs and treatment efficacy for people with Type 1 and Type 2 diabetes in the United Kingdom from 1997 to 2007 * , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[56]  M. Evans,et al.  Dispensing patterns and financial costs of glucose‐lowering therapies in the UK from 2000 to 2008 * , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[57]  J. Yudkin,et al.  Looking beyond the issue of access to insulin: what is needed for proper diabetes care in resource poor settings. , 2010, Diabetes research and clinical practice.

[58]  J. Probst,et al.  Diabetes Care and Outcomes: Disparities Across Rural America , 2010, Journal of Community Health.

[59]  Michael R. Reich,et al.  Access: How Do Good Health Technologies Get to Poor People in Poor Countries? , 2009 .

[60]  D Ross-Degnan,et al.  Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis , 2009, The Lancet.

[61]  D. Simmons,et al.  Diabetes risk factors, diabetes and diabetes care in a rural Australian community. , 2007, The Australian journal of rural health.

[62]  A. Berghold,et al.  Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. , 2007, The Cochrane database of systematic reviews.

[63]  T R Pieber,et al.  Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. , 2006, The Cochrane database of systematic reviews.

[64]  M. D. de Courten,et al.  Access to care for patients with insulin-requiring diabetes in developing countries: case studies of Mozambique and Zambia. , 2005, Diabetes care.

[65]  Fiona Fleck.  In brief , 2002, BMJ : British Medical Journal.

[66]  T. Jones.  Diabetes Mellitus: the increasing burden of disease in Kenya , 2013 .

[67]  P. Kanavos,et al.  Diabetes expenditure, burden of disease and management in 5 EU countries , 2012 .

[68]  D. Beran.  Improving access to insulin: what can be done? , 2011 .

[69]  H. Keen,et al.  The insulin dilemma in resource-limited countries. A way forward? , 2010, Diabetologia.